Cardiovascular Outcomes
Cardiovascular outcome evidence in diabetes and metabolism, including MACE, heart failure, renal outcomes, lipid therapy, hypertension, and cardiometabolic risk reduction.
Intraoperative Dexmedetomidine Reduces Glucose Variability and Insulin Requirements in Diabetic CABG Patients
An RCT finds intraoperative dexmedetomidine reduces glucose variability, insulin requirements, and CRP in diabetic off-pump CABG patients, though endpoints are surrogate. PICO summary and commentary.
Does BMI Affect the Benefits of Bivalirudin Over Heparin in Heart Attack Patients?
A prespecified BRIGHT-4 subgroup analysis finds bivalirudin reduces death or major bleeding versus heparin in lower-BMI STEMI patients but not higher-BMI, with a significant interaction. PICO summary and commentary.
Tai Chi Cardiac Rehabilitation Reduces Psychological and Oxidative Stress in Chronic Coronary Syndrome: RCT
A small RCT finds a 12-week hybrid Tai Chi cardiac rehab programme reduces perceived stress and oxidised LDL more than conventional exercise in chronic coronary syndrome. PICO summary and commentary.
Is Indobufen-Based Antiplatelet Therapy Consistent in Diabetic Patients After Stenting? OPTION Analysis
An OPTION post-hoc analysis finds indobufen-based antiplatelet therapy after stenting performs consistently regardless of diabetes status, with a similar bleeding advantage. PICO summary and commentary.
Does Dapagliflozin Improve Coronary Blood Flow in Diabetes? DAPAHEART 4-Year Follow-up
The 4-year DAPAHEART follow-up finds dapagliflozin raises coronary flow reserve by 34% and reduces epicardial fat, apparently independent of weight loss. PICO summary and commentary.
Do Disease-Modifying Medications Improve Lipid Levels in Heart Disease?
An RCT finds triple therapy with a statin, SGLT2 inhibitor, and PCSK9 inhibitor lowers lipids more than monotherapy in ischemic heart disease. PICO summary and commentary.
